PITTSBURGH, Nov. 18 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Didier Barret, president of Mylan Europe, Middle East and Africa (EMEA), has been elected president of the European Generic Medicines Association (EGA). Barret was elected to a two-year term earlier today at the EGA annual meeting being held in Brussels.
Mylan Chairman and CEO Robert J. Coury said: "We are extremely pleased to have one of our own senior executives lead Europe's generic trade organization over the next two years. The EGA could not have elected a stronger leader to help guide our industry in Europe than Didier Barret. His willingness to serve EGA in this capacity emphasizes Mylan's commitment to enhance industry efforts in international markets as generic pharmaceuticals represent a proven and successful solution to rising global health care costs."
Commenting on his appointment Barret said: "I am very proud to be able to serve EGA as president. One of my goals is to replicate the kind of strong collaboration that Mylan has had with the industry associations across the world. I also look forward to continuing to help shape the European generics marketplace as a facilitator between the industry and our colleagues at health care agencies across the different European regions. Creating conditions for a sustainable and competitive generics industry within the European market will be a priority for EGA in the years ahead."
The EGA is the official representative body of the European generic and bio-similar pharmaceutical industry, which is at the forefront of providing high quality affordable medicines to millions of Europeans and stimulating competitiveness and innovation in the pharmaceutical sector. Formed in 1993, the EGA represents generic pharmaceuticals companies and their subsidiaries throughout Europe, either directly or through national associations.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.
SOURCE Mylan Inc.
|SOURCE Mylan Inc.|
Copyright©2009 PR Newswire.
All rights reserved